1月7日，京东健康医疗器械开新盛典在北京举行。会上，京东健康互联网医疗业务负责人出席并发表主 题演讲，系统分享了在互联网医疗高速发展的背景下，京东互联网医院如何通过构建全场景、全流程的 医疗服务能力，为医疗器械品牌增长与用户健康管理提供深度助力。 服务创新与闭环构建 引领医疗健康一体化新体验 当前，互联网医疗正迎来广泛普及与高速发展阶段。据行业预测，2025年我国互联网医疗市场规模将达 4799亿元，用户规模已突破4亿。京东互联网医院作为国内首批取得牌照的独立设置型互联网医院之 一，持续巩固"在线诊疗第一入口"地位，日均问诊咨询量超过50万，客户满意度达98.9%。 在持续提升综合服务能力的同时，京东互联网医院也重点加强了专科专病服务体系的建设。目前已陆续 升级皮肤医院、精神心理中心及中医院，并于2025年新增男科与肿瘤专科，与全国知名专家共建专病工 作室，持续夯实其在重点专科领域的服务深度与专业厚度。 如今，京东健康已建成覆盖"医、检、诊、药"的一站式闭环服务。从线上问诊、检验单开具、护士上门 检测，到报告解读、药品配送，用户足不出户即可完成全流程诊疗。此外，还支持全国多城市的影像检 查预约，进一步拓展了服 ...

坐落在岳麓山脚下的国家超级计算长沙中心，超算算力跻身全国前列。 长沙聚焦"4433"现代化产业体系，持续发力打造国家重要先进制造业高地。 梯度培育 激活企业成长新动能 企业是制造业的核心载体，更是高质量发展的活力源泉。长沙深谙"独木不成林，百木汇成森"的发展之道，通过"千 百十"梯度培育工程，让不同规模、不同发展阶段的企业都能找准赛道、梯次进阶，最终形成大中小企业融通发展、 共生共荣的产业生态。 在这一融通共生的生态中，龙头企业扮演着关键角色，它们既是抵御市场风浪的"压舱石"，更是引领产业升级的"领 航者"。 中联重科挖机列阵，助力"长沙智造"腾飞。 紫金矿业长沙新能源公司生产实验车间。 中联智慧产业城里，AGV小车沿着磁导航轨道无声穿梭，机械臂精准焊接，平均每６分钟就有一台"长沙智造"的挖机 设备下线；在广汽埃安的生产基地，新能源汽车驶下流水线，动力电池与整车协同创新，续航里程再破新纪录，奔赴 全国乃至全球市场；在湘江鲲鹏的研发中心，自主创新芯片点亮屏幕，"两芯一生态"体系构筑信创产业安全屏障，多 款产品市场占有率全国领先…… 这是2025年长沙制造业的生动场景，更是创新活力奔涌的真实写照。从车间流水线到实 ...

Core Viewpoint - Ping An Property & Casualty Insurance's Shaoguan Center initiated a public welfare project aimed at enhancing rural healthcare through the donation of medical supplies, emphasizing the importance of health security in rural revitalization [2][10]. Group 1: Project Overview - The "Ping An Rural Revitalization Public Welfare Plan - Medical Outreach Project" was launched on December 30, 2025, in Shaoguan City [2]. - The project commenced simultaneously in two villages: Liao Zhou Water Village in Shixing County and Yangshi Village in Xinfeng County [3]. Group 2: Medical Supplies Donation - The donation involved practical medical supplies aimed at improving the healthcare service capacity at the grassroots level [4]. - The distribution of medical supplies was based on prior field research data, specifically targeting the needs of the elderly population in rural areas for chronic disease management and emergency medical response [5][6]. Group 3: Implementation and Management - During the donation ceremony, the Shaoguan Center formally transferred the supplies to village representatives and signed a receipt to ensure the materials would be prioritized for village health clinics and needy families [7][8]. - The village committees committed to strict management of the donated medical resources, including establishing a special ledger for tracking the usage of supplies and conducting regular inspections [13][14]. Group 4: Future Commitment - The project reflects the company's commitment to the "insurance + public welfare" model and its dedication to serving grassroots communities [16][17]. - The Shaoguan Center plans to continue focusing on rural healthcare deficiencies, collaborating with various resources to promote the distribution of quality medical resources, thereby contributing to the dual goals of a healthy China and rural revitalization [20][21].

"我这么瘦，怎么会患妊娠期糖尿病？""我只是血糖高一点，生完孩子就好了，应该没什么关系 吧？"……在妇产科，准妈妈们类似的问题几乎每天都能听到。随着生活方式的改变和诊断标准的更 新，妊娠期糖尿病已成为我国孕期最常见的并发症之一。本文旨在澄清公众对妊娠期糖尿病的常见误 区，提供科学、实用的知识，帮助准妈妈们正确认识、积极应对这一"甜蜜的负担"。 我国妊娠期糖尿病发病率仍在上升 最新的流行病学数据显示，我国妊娠期糖尿病发病率高达17.5%，相当于每6位孕妇中就有1位面临这一 问题。随着二孩、三孩政策的开放和高龄孕妇比例的增加，这一数字仍在上升。 然而，公众对妊娠期糖尿病的认知却存在显著不足与误区。许多准妈妈要么过度焦虑，要么不当回事， 这两种态度都可能对母婴健康造成不利影响。 妊娠期糖尿病，是指妊娠期间首次发生或发现的不同程度的糖代谢异常。这主要由于妊娠期胎盘分泌的 激素（如孕激素、雌激素）会对抗胰岛素的作用，导致胰岛素抵抗增加。当孕妇的胰岛功能无法代偿这 种抵抗时，血糖就会升高。 绝大多数妊娠期糖尿病发生在孕24～28周，且多数在产后能恢复正常。但它显著增加未来患2型糖尿病 的风险。因此，糖尿病筛查对孕妇来说非 ...

近日，鱼跃医疗在互动平台向投资者表示，公司的多款健康设备，如血糖仪、血压计、呼吸机等，均有 部分型号已经接入了蚂蚁阿福的健康管理系统，设备的监测数据可以自动同步到用户的个人健康档案 中，方便用户长期追踪和管理健康状况。此外，公司推出的"鱼跃安耐糖""鱼跃呼吸管家""鱼跃血压管 家"等AI智能体也上线了蚂蚁阿福应用，能够基于用户的健康数据提供个性化的健康管理建议。 2025年 1至9月，鱼跃医疗实现营收65.45亿元，同比增长8.58%（调整后）；实现归母净利润14.66亿元，同比 下降4.28%（调整后）。 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its performance relative to the market [6]. Core Insights - The strategic partnership between the company and Royal Philips aims to enhance the availability of high-quality health technology products in the Chinese market, focusing on various home health monitoring devices [4][6]. - The collaboration is expected to leverage Philips' technological expertise and brand resources alongside the company's strengths in innovation, manufacturing, and channel operations, creating a comprehensive health management ecosystem for Chinese families [6]. - The report anticipates long-term growth for the company, despite a downward adjustment in profit forecasts for 2025 and 2026 due to overall domestic demand fluctuations [6]. Financial Data and Profit Forecast - Projected total revenue for 2025 is estimated at 3,348 million yuan, reflecting a year-on-year growth rate of 12.3% [5]. - The forecasted net profit attributable to the parent company for 2025 is 391 million yuan, with a growth rate of 25.3% [5]. - Earnings per share (EPS) for 2025 is expected to be 1.87 yuan, with a price-to-earnings (PE) ratio of 24 times [5]. - The company’s net profit is projected to reach 592 million yuan by 2027, with a PE ratio of 16 times, significantly lower than the overall medical device industry PE of 38 times for 2025 [6].

可孚医疗引入飞利浦家庭健康监测设备 可孚医疗(301087) 公司调研简报 股票研究 / [Table_Date] 2025.12.15 2025-12-15 [Table_Industry] 医药/必需消费 本报告导读： 我国家用医疗器械领军企业可孚医疗与皇家飞利浦（Royal Philips）正式签署战略合 作协议。双方将围绕多款家庭健康监测设备开展深度合作，让高品质健康科技产品 更广泛地进入我国市场。 投资要点： 股 票 研 究 公 司 调 研 简 报 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 [table_Authors] 风险提示。海外经营环境风险，新业务条线开拓进展不及预期风险。 [Table_Finance] 财务摘要(百万元) 2023A 2024A 2025E 2026E 2027E 营业总收入 2,854 2,983 3,358 3,819 4,366 (+/-)% -4.1% 4.5% 12.6% 13.7% 14.3% 净利润(归母) 254 312 375 456 530 (+/-)% -15.7% 22.6% 20.3% 21.7% 16.2% 每股净收益(元) 1 ...

股 票 研 究 可孚医疗引入飞利浦家庭健康监测设备 可孚医疗(301087) 公司调研简报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 孟陆(分析师) | 010-56535972 | menglu@gtht.com | S0880525040073 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | 本报告导读： 我国家用医疗器械领军企业可孚医疗与皇家飞利浦（Royal Philips）正式签署战略合 作协议。双方将围绕多款家庭健康监测设备开展深度合作，让高品质健康科技产品 更广泛地进入我国市场。 投资要点： | | | [Table_Industry] 医药/必需消费 | [Table_Invest] 评级： | 增持 | | --- | --- | | [Table_Target] 目标价格(元): | 53.84 | [Table_Market] 交易数据 | 52 周内股价区间(元) | 30.48-46.02 | | --- | ...

Core Insights - Kefu Medical, a leading Chinese home medical device company, has signed a strategic cooperation agreement with Royal Philips to enhance the availability of high-quality health technology products in Chinese households [1][3]. Group 1: Company Overview - Kefu Medical has over 20 years of experience in the industry and has established a comprehensive system covering research and development, production, distribution, e-commerce, and logistics [3]. - The company exports its products to over 60 countries and regions globally and holds a significant position in both online and offline markets in China [3]. Group 2: Strategic Partnership - The agreement allows Kefu Medical to obtain brand authorization for multiple home health monitoring devices from Royal Philips, including blood glucose meters, blood pressure monitors, continuous glucose monitoring devices (CGM), thermometers, pulse oximeters, pulmonary function meters, and scales [3]. - The partnership aims to create smart health management solutions tailored to the needs of Chinese families, promoting a new era of precision, intelligence, and contextualization in the domestic health monitoring sector [3]. Group 3: Product Development and Market Strategy - The first batch of Royal Philips smart monitoring medical devices is in the preparation stage for market launch, focusing on innovative and forward-looking product solutions for consumers [4]. - Future products will leverage enhanced online channel strategies to solidify market leadership, utilizing Kefu Medical's retail system, national and regional distribution networks, major chain pharmacies, specialized medical device stores, and clinics for rapid business expansion and coverage [4].

Group 1: Strategic Partnerships - Royal Philips has granted Kefu Medical brand authorization for various home health monitoring devices in Greater China, including blood glucose meters, blood pressure monitors, thermometers, and pulse oximeters, following a comprehensive evaluation of the company's capabilities [2] - The collaboration aims to deepen R&D synergy and localization, integrating international branding with leading Chinese technology and industrial capabilities [2] Group 2: Overseas Business Growth - Kefu Medical has made significant progress in its global strategy, achieving high growth in overseas business due to accumulated customer resources and enhanced customer loyalty [2] - B2B order amounts are steadily increasing, supported by successful integration of acquisitions such as Huazhou and Ximan, which are releasing synergistic effects for sustained international business growth [2] Group 3: Product Development in Respiratory Sector - The respiratory machine segment focuses on user needs, with plans to launch three new respiratory machines and masks in 2026, incorporating AI algorithms for real-time sleep analysis and advanced noise reduction technology [3] - Kefu's respiratory machines have seen rapid sales growth since launch, achieving leading performance in both product capabilities and online sales channels, driving revenue growth for the second half of the year and beyond [3] Group 4: Future Development Plans - Over the next 3-5 years, Kefu Medical will focus on independent innovation and global expansion, while deepening strategic cooperation with Royal Philips to promote high-quality development [4] - The company plans to increase R&D investment in core categories such as respiratory health, hearing assistance, rehabilitation care, and home testing, aiming for product intelligence upgrades and the establishment of a proprietary technology platform [4] - Kefu Medical will enhance its overseas localization capabilities and steadily expand its international market presence through a combination of organic growth and acquisition strategies [4]